Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
Cidara Therapeutics (Nasdaq: CDTX) will report third quarter 2025 financial results and operational highlights after market close on Thursday, November 6, 2025, followed by a conference call and webcast at 5:00 PM ET (Conference ID: 10203589; US dial-in 1-844-825-9789).
The company develops drug‑Fc conjugate (DFC) immunotherapies using the Cloudbreak platform. Its lead DFC, CD388, is a long‑acting antiviral for universal influenza prevention; CD388 received FDA Fast Track designation in June 2023, reported positive top‑line Phase 2b NAVIGATE results in June 2025, and initiated the Phase 3 ANCHOR trial in September 2025.
Cidara Therapeutics (Nasdaq: CDTX) proporrà i risultati finanziari del terzo trimestre 2025 e i principali highlights operativi dopo la chiusura del mercato giovedì 6 novembre 2025, seguito da una conference call e webcast alle 17:00 ET (Conference ID: 10203589; US dial-in 1-844-825-9789).
L’azienda sviluppa immunoterapie con coniugati drug‑Fc (DFC) utilizzando la piattaforma Cloudbreak. Il suo DFC leader, CD388, è un antivirale a lunga durata per la prevenzione universale dell’influenza; CD388 ha ricevuto la designazione FDA Fast Track nel giugno 2023, ha riportato positivi risultati topline di fase 2b NAVIGATE a giugno 2025 e ha avviato il trial di fase 3 ANCHOR nel settembre 2025.
Cidara Therapeutics (Nasdaq: CDTX) informará sobre los resultados financieros del tercer trimestre de 2025 y los aspectos operativos destacados después del cierre del mercado el jueves 6 de noviembre de 2025, seguido por una llamada de conferencia y webcast a las 5:00 PM ET (Conference ID: 10203589; US dial-in 1-844-825-9789).
La empresa desarrolla inmunoterapias de conjugados drug‑Fc (DFC) utilizando la plataforma Cloudbreak. Su DFC líder, CD388, es un antiviral de acción prolongada para la prevención universal de la gripe; CD388 recibió la designación FDA Fast Track en junio de 2023, informó resultados positivos de la línea principal de la fase 2b NAVIGATE en junio de 2025 y inició el ensayo de fase 3 ANCHOR en septiembre de 2025.
Cidara Therapeutics (나스닥: CDTX)는 2025년 3분기 재무 실적 및 운영 하이라이트를 2025년 11월 6일 목요일 시장 마감 후 발표하고, 이어 동부 표준시 17:00에 컨퍼런스 콜 및 웹캐스트가 진행되며(회의 ID: 10203589; 미국 다이얼인 1-844-825-9789).
회사는 Cloudbreak 플랫폼을 사용하여 약물-Fc 결합 면역요법(DFC)을 개발합니다. 주요 DFC인 CD388은 만연한 독감을 위한 장기간 작용 항바이러스제이며, CD388은 2023년 6월에 FDA Fast Track 지정을 받았고, 2025년 6월에 2상 NAVIGATE의 긍정적 초기 결과를 발표했으며 2025년 9월에 3상 ANCHOR 시험을 시작했습니다.
Cidara Therapeutics (Nasdaq : CDTX) publiera les résultats financiers du troisième trimestre 2025 et les points opérationnels clés après la clôture du marché le jeudi 6 novembre 2025, suivis d'une conférence téléphonique et d'une webdiffusion à 17h00 ET (Conference ID : 10203589 ; US dial-in 1-844-825-9789).
L'entreprise développe des immunothérapies à conjugaison drug‑Fc (DFC) en utilisant la plateforme Cloudbreak. Son DFC principal, CD388, est un antiviral à longue durée d'action pour la prévention universelle de la grippe; CD388 a reçu la désignation FDA Fast Track en juin 2023, a rapporté des résultats positifs en phase 2b NAVIGATE en juin 2025 et a lancé l'essai de phase 3 ANCHOR en septembre 2025.
Cidara Therapeutics (Nasdaq: CDTX) wird die Finanzergebnisse des dritten Quartals 2025 und operative Highlights nach Börsenschluss am Donnerstag, 6. November 2025 berichten, gefolgt von einem Conference Call und Webcast um 17:00 Uhr ET (Conference ID: 10203589; US-Dial-in 1-844-825-9789).
Das Unternehmen entwickelt Drug-Fc-Conjugate (DFC)-Immuntherapien mithilfe der Cloudbreak-Plattform. Sein führendes DFC, CD388, ist ein lang wirkendes antivirales Mittel zur universellen Grippeprävention; CD388 erhielt im Juni 2023 die FDA Fast Track-Zulassung, berichtete im Juni 2025 von positiven Topline-Ergebnissen der Phase 2b NAVIGATE und begann im September 2025 die Phase-3-Studie ANCHOR.
Cidara Therapeutics (بورصة ناسداك: CDTX) ستعلن عن النتائج المالية للربع الثالث من 2025 واللمحات التشغيلية بعد إغلاق السوق يوم الخميس 6 نوفمبر 2025، يليها مكالمة مؤتمرات وبث حي في 5:00 مساءً بتوقيت شرق الولايات المتحدة (معرف المؤتمر: 10203589؛ الولايات المتحدة dial-in 1-844-825-9789).
الشركة تطور علاجات مناعية بالارتباط Drug-Fc (DFC) باستخدام منصة Cloudbreak. DFC الرئيسي لديها، CD388، هو مضاد فيروسي طويل الأجل للوقاية الشاملة من الإنفلونزا؛ CD388 حصل على ترخيص FDA Fast Track في يونيو 2023، أبلغ عن نتائج إيجابية في المرحلة 2b NAVIGATE في يونيو 2025 وبدأ تجربة المرحلة 3 ANCHOR في سبتمبر 2025.
- CD388 received FDA Fast Track designation in June 2023
- Positive Phase 2b NAVIGATE top‑line results announced June 2025
- Initiated Phase 3 ANCHOR trial in September 2025
- Scheduled Q3 2025 results and investor call on Nov 6, 2025
- None.
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, November 6, 2025 |
| Time: | 5:00 PM Eastern Time |
| United States: | 1-844-825-9789 |
| International: | 1-412-317-5180 |
| Conference ID: | 10203589 |
| Webcast: | Link |
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara (CDTX) report Q3 2025 results and hold the conference call?
How can investors join the Cidara (CDTX) Q3 2025 webcast and what is the conference ID?
What is Cidara's lead candidate CD388 and what recent clinical milestones has CD388 achieved?
Has Cidara (CDTX) started a Phase 3 trial for CD388 and when did it begin?
Where is Cidara Therapeutics headquartered and how can investors get more information?
